Hypercalcemia in patients with thyroid cancer: malignancy-related mechanisms, differential diagnosis, and management

Abstract Hypercalcemia associated with malignancy (HAM) represents a critical metabolic oncological emergency that signifies advanced systemic disease and carries prognostic significance. Although its prevalence in thyroid cancer is relatively low, affecting approximately 6.3% of patients in a historical terminal-stage cohort, it serves as a marker for aggressive tumor phenotypes and dedifferentiation. The pathophysiology is categorized into four recognized mechanisms, which may overlap: humoral hypercalcemia of malignancy (HHM) driven by systemic parathyroid hormone-related protein (PTHrP) secretion; local osteolytic hypercalcemia (LOH) resulting from direct bone destruction by metastatic cells; 1,25-dihydroxyvitamin D-mediated hypercalcemia; and the exceedingly rare ectopic secretion of authentic parathyroid hormone (PTH). Notably, anaplastic thyroid cancer (ATC) may present with a dual paraneoplastic syndrome involving concurrent systemic PTHrP secretion and a leukemoid reaction, whereas hypercalcemia in medullary thyroid cancer (MTC) often reflects benign parathyroid pathology associated with multiple endocrine neoplasia type 2 A (MEN2A), which is hypercalcemia in a patient with cancer rather than hypercalcemia caused by the malignancy. Diagnostic evaluation requires a systematic approach organized around PTH-dependent and PTH-independent hypercalcemia, including biochemical assessment of PTH, PTHrP, and vitamin D metabolites, with imaging selected according to tumor histology and the suspected mechanism. Management prioritizes individualized volume repletion, pharmacological suppression of osteoclast activity with denosumab or an intravenous bisphosphonate, current guidance conditionally favouring denosumab, and targeted oncological interventions. Ultimately, the onset of HAM in most thyroid malignancies remains an indicator of poor survival, necessitating a multidisciplinary approach to optimize both clinical outcomes and palliative quality of life. Thyroid-cancer-specific evidence remains limited and is derived largely from case reports and from extrapolation of general hypercalcemia-of-malignancy literature.

Authors

Institutions

Publication Details

Journal
Endocrine
Published
2026-11-16
DOI
https://doi.org/10.1007/s12020-026-04846-7
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hypercalcemia in patients with thyroid cancer: malignancy-related mechanisms, differential diagnosis, and management

Lucas Leite Cunha, Laura Sterian Ward, Marise Lazaretti‐Castro, Jean Ferrante Mariano
Endocrine
Thyroid Cancer Diagnosis and Treatment
article

Hypercalcemia in patients with thyroid cancer: malignancy-related mechanisms, differential diagnosis, and management

Lucas Leite Cunha, Laura Sterian Ward, Marise Lazaretti‐Castro, Jean Ferrante Mariano
article en

Abstract

Abstract Hypercalcemia associated with malignancy (HAM) represents a critical metabolic oncological emergency that signifies advanced systemic disease and carries prognostic significance. Although its prevalence in thyroid cancer is relatively low, affecting approximately 6.3% of patients in a historical terminal-stage cohort, it serves as a marker for aggressive tumor phenotypes and dedifferentiation. The pathophysiology is categorized into four recognized mechanisms, which may overlap: humoral hypercalcemia of malignancy (HHM) driven by systemic parathyroid hormone-related protein (PTHrP) secretion; local osteolytic hypercalcemia (LOH) resulting from direct bone destruction by metastatic cells; 1,25-dihydroxyvitamin D-mediated hypercalcemia; and the exceedingly rare ectopic secretion of authentic parathyroid hormone (PTH). Notably, anaplastic thyroid cancer (ATC) may present with a dual paraneoplastic syndrome involving concurrent systemic PTHrP secretion and a leukemoid reaction, whereas hypercalcemia in medullary thyroid cancer (MTC) often reflects benign parathyroid pathology associated with multiple endocrine neoplasia type 2 A (MEN2A), which is hypercalcemia in a patient with cancer rather than hypercalcemia caused by the malignancy. Diagnostic evaluation requires a systematic approach organized around PTH-dependent and PTH-independent hypercalcemia, including biochemical assessment of PTH, PTHrP, and vitamin D metabolites, with imaging selected according to tumor histology and the suspected mechanism. Management prioritizes individualized volume repletion, pharmacological suppression of osteoclast activity with denosumab or an intravenous bisphosphonate, current guidance conditionally favouring denosumab, and targeted oncological interventions. Ultimately, the onset of HAM in most thyroid malignancies remains an indicator of poor survival, necessitating a multidisciplinary approach to optimize both clinical outcomes and palliative quality of life. Thyroid-cancer-specific evidence remains limited and is derived largely from case reports and from extrapolation of general hypercalcemia-of-malignancy literature.

EndocrineVol. 91(1)
Universidade Estadual de Campinas (UNICAMP) (BR), AC Camargo Hospital (BR), Universidade Federal de São Paulo (BR)
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon